EN DE
Watch Eupraxia Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Eupraxia Pharmaceuticals Inc (EPRX) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Eupraxia Pharmaceuticals Inc stock C$7.63, price C$10.56, that is 27.7% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA29842P1053

EP Eupraxia Pharmaceuticals Inc logo Thin data Nov 15, 2026

Eupraxia Pharmaceuticals Inc

EPRX · TO

Expensive (fair value 28% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Fair value C$7.63 · Overvalued 
Quality 34/100 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Eupraxia Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$12.99 C$0.9000 Fair Value C$7.63 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range C$0.9000 – C$12.99 · fair‑value band C$5.72 – C$9.53 · the C$10.56 price screens above the C$7.63 fair value. As of Nov 15, 2026.

Follow Eupraxia Pharmaceuticals in your weekly email

Every Wednesday you see whether Eupraxia Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.

Show moreShow less

The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis.

The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Stock analysis

Eupraxia Pharmaceuticals Inc (EPRX) currently trades at C$10.56, while our estimate is C$7.63, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$5.72 (bear) to C$9.53 (bull), the price of C$10.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Eupraxia Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$39.3M in FY2025.

Key figures

Market cap C$710M (≈ $496M) Small · EPS (TTM) C$−1.41 · Return on equity −56.4% · Return on assets (EBIT) −83.0% (5-year average) · Free cash flow −C$29.7M · Net cash C$80.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −28%, EPRX screens richer than that median.

Fair Value

Bear C$5.72 Fair Value C$7.63 Bull C$9.53
Price C$10.56 · Downside -27.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 18
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 53
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EPRX screens overvalued: fair value 28% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Eupraxia Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 0/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −27.7% · Below median
Profitability
Return on assets −45.6% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.06× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs EPRX
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs EPRX
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs EPRX
argenx SE ARGX $950.95 $908.40 −4% vs EPRX
CSL Limited CSL A$199.55 A$186.49 −7% vs EPRX
Moderna, Inc MRNA $215.27 $135.64 −37% vs EPRX
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs EPRX
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs EPRX
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs EPRX
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs EPRX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Eupraxia Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Eupraxia Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/EPRX

Frequently asked questions

Is Eupraxia Pharmaceuticals Inc (EPRX) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is C$7.63 versus a price of C$10.56, about 28% lower (overvalued).
What is the fair value of EPRX?
Our estimate for Eupraxia Pharmaceuticals Inc is C$7.63 (as of Nov 15, 2026), built from audited fundamentals. The current price: C$10.56.
What is the quality score of EPRX?
Eupraxia Pharmaceuticals Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eupraxia Pharmaceuticals Inc (EPRX)?
Our calculated price target is the estimate of C$7.63 (as of Nov 15, 2026). Cautious scenario C$5.72, optimistic scenario C$9.53. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Eupraxia Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at C$7.63, about 28% lower versus a price of C$10.56 (overvalued). Cautious scenario C$5.72, optimistic scenario C$9.53. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Eupraxia Pharmaceuticals Inc (EPRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eupraxia Pharmaceuticals Inc it is C$7.63 per share (as of Nov 15, 2026), against a price of C$10.56.
Is Eupraxia Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 15, 2026, EPRX trades above its calculated fair value: price C$10.56, fair value C$7.63, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EPRX?
No. The price is what the market pays today (C$10.56); the fair value is what the company's own numbers justify (C$7.63). For Eupraxia Pharmaceuticals Inc the two are C$2.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eupraxia Pharmaceuticals Inc worth?
The market values Eupraxia Pharmaceuticals Inc at about C$710M (market capitalisation, as of Nov 15, 2026). Per share that is C$10.56; our models calculate a fair value of C$7.63 per share.
What do the bullish and bearish scenarios say about EPRX?
Our models span a range for Eupraxia Pharmaceuticals Inc: cautious scenario C$5.72, base C$7.63, optimistic C$9.53 per share (as of Nov 15, 2026, price C$10.56). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Eupraxia Pharmaceuticals Inc (EPRX)?
Balance-sheet figures for Eupraxia Pharmaceuticals Inc (as of Nov 15, 2026): return on equity −56.4%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is EPRX from its 52-week high?
Eupraxia Pharmaceuticals Inc trades at C$10.56, about 19% below its 52-week high of C$12.99 and 31% above the low of C$8.06 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of C$7.63 is for.
Which stocks are comparable to Eupraxia Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eupraxia Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 15, 2026: price C$10.56, calculated fair value C$7.63 (−28%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Eupraxia Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eupraxia Pharmaceuticals Inc (EPRX)?
The closing price on Nov 16, 2026 was C$10.56. Our estimate is C$7.63, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eupraxia Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case (C$9.53). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Eupraxia Pharmaceuticals Inc

How large is the market capitalisation of Eupraxia Pharmaceuticals Inc (EPRX)?
The market capitalisation of Eupraxia Pharmaceuticals Inc is C$710M (≈ $496M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Eupraxia Pharmaceuticals Inc (EPRX)?
Earnings per share at Eupraxia Pharmaceuticals Inc are C$−1.41. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Eupraxia Pharmaceuticals Inc (EPRX)?
The return on equity (ROE) of Eupraxia Pharmaceuticals Inc is −56.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eupraxia Pharmaceuticals Inc (EPRX)?
On an EBIT basis the return on assets of Eupraxia Pharmaceuticals Inc is −83.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Eupraxia Pharmaceuticals Inc (EPRX) generate?
The free cash flow of Eupraxia Pharmaceuticals Inc is −C$29.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Eupraxia Pharmaceuticals Inc (EPRX) hold?
Eupraxia Pharmaceuticals Inc holds more cash than debt, C$80.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Eupraxia Pharmaceuticals Inc in the live analysis

One click puts Eupraxia Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.